Faruk Eroglu, MD, Mehmet Çakır, MD, Aydın Yıldrım, MD, Hanefi Çakır, MD, Nusret Bas, MD, A.Kadir Egemenoglu, MD, Ahmet Bas, MD, H.Hüseyin Altunbas, MD, Demir Basar, MD, Türkiye Hospital Eye Clinic, Istanbul, Turkey


To evaluate the efficacy and safety of 1 intravitreal 4mg triamcinolone acetonide (IVTA) for treatment of diabetic macular edema (DME).


The prospective clinical interventional study included 24 eyes of 14 patients who underwent 4mg/01 cc IVTA Injection under topical anaesthesia for treatment of DME. All patients were followed-up at least 3 months. Preoperative and postoperative visual acuity, scanning laser ophthalmoscopic (SLO) angiographic findings, intraocular pressure measurements and cataract progressions were evaluated.


The average follow-up time was 5 (6-9) months. Mean visual acuity was 0.12 (0.01-0.4) snellen line preoperatively and 0.34 (0.05-0.9) snellen line postoperatively. Previously 17 eyes of 9 patients had grid laser photocoagulation treatments. Angiographically there was diffuse macular edema in 20 eyes, cystoid macular edema in 3 eyes and focal edema in 1 eye. In all eyes angiographic edema reduced. Only in 1 patient (1 eye) intraocular pressure elevated and was controlled by topical antiglaucomatous medication. There was not any cataract progression.


IVTA injection effectively reduces macular edema especially in diffuse edema refractory to grid laser photocoagulation. With this treatment, we can provide additional visual improvements.

Take-home message:

Intravitreal injections of triamcinolone acetonide may be an additional tool in the treatment of diabetic macular edema.